Literature DB >> 11572110

[Pathology of important diseases of endocrine organs (excluding the thyroid)].

W Saeger1, S Schröder, G Klöppel.   

Abstract

Basic principles of classification of tumors of the pituitary, parathyroid glands, adrenals, paraganglionic system and endocrine pancreas and the differential diagnosis from non-endocrine tumors are presented. There are no uniform criteria of malignancy and common neuroendocrine immunohistological markers for unequivocal identification, as each organ has its own criteria. For pituitary tumors invasive growth is not a sign of malignancy, but only metastases. For tumors of the adrenal cortex a histopathological score has to be used for proving dignity. For pheochromocytomas, structural criteria (mitoses, angioinvasion) and immunostaining (S-100 protein, p53, Ki-67) are important. Endocrine tumors of the pancreas behave differently if they are angioinvasive or if they show more than two mitoses per 10 HPF, more than 2% Ki-67 positive nuclei or a size of more than 2 cm in diameter. They are malignant if gross local invasion or metastases are demonstrable. Clinical data have to be included in pathohistological reports. In many cases immunostaining in addition to structural analysis will be necessary.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11572110     DOI: 10.1007/s002920100483

Source DB:  PubMed          Journal:  Pathologe        ISSN: 0172-8113            Impact factor:   1.011


  4 in total

1.  [Inflammations of endocrinal organs].

Authors:  W Saeger
Journal:  Pathologe       Date:  2016-05       Impact factor: 1.011

Review 2.  [Pituitary gland tumors].

Authors:  W Saeger
Journal:  Pathologe       Date:  2003-05-29       Impact factor: 1.011

Review 3.  [Space occupying processes of the sellar region with emphasis on tumor-like lesions].

Authors:  W Saeger
Journal:  Pathologe       Date:  2003-05-29       Impact factor: 1.011

Review 4.  [Adrenocortical tumours].

Authors:  W Saeger
Journal:  Pathologe       Date:  2003-05-06       Impact factor: 1.011

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.